294 related articles for article (PubMed ID: 28340861)
1. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
D'Urzo A; Rennard S; Kerwin E; Donohue JF; Lei A; Molins E; Leselbaum A
Respir Med; 2017 Apr; 125():39-48. PubMed ID: 28340861
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
3. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
Donohue JF; Soong W; Wu X; Shrestha P; Lei A
Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
[TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).
Bateman ED; Chapman KR; Singh D; D'Urzo AD; Molins E; Leselbaum A; Gil EG
Respir Res; 2015 Aug; 16(1):92. PubMed ID: 26233481
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
[TBL] [Abstract][Full Text] [Related]
7. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.
D'Urzo AD; Singh D; Donohue JF; Kerwin EM; Ribera A; Molins E; Chuecos F; Jarreta D; Gil EG
Int J Chron Obstruct Pulmon Dis; 2019; 14():479-491. PubMed ID: 30880938
[TBL] [Abstract][Full Text] [Related]
9. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD.
Sethi S; Kerwin E; Watz H; Ferguson GT; Mroz RM; Segarra R; Molins E; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2019; 14():667-682. PubMed ID: 30962681
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Hanania NA; Tashkin DP; Kerwin EM; Donohue JF; Denenberg M; O'Donnell DE; Quinn D; Siddiqui S; Orevillo C; Maes A; Reisner C
Respir Med; 2017 May; 126():105-115. PubMed ID: 28427541
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study.
Singh D; Jones PW; Bateman ED; Korn S; Serra C; Molins E; Caracta C; Gil EG; Leselbaum A
BMC Pulm Med; 2014 Nov; 14():178. PubMed ID: 25404569
[TBL] [Abstract][Full Text] [Related]
12. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD.
Watz H; Troosters T; Beeh KM; Garcia-Aymerich J; Paggiaro P; Molins E; Notari M; Zapata A; Jarreta D; Garcia Gil E
Int J Chron Obstruct Pulmon Dis; 2017; 12():2545-2558. PubMed ID: 28883722
[TBL] [Abstract][Full Text] [Related]
13. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
14. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
15. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.
D'Urzo AD; Singh D; Donohue JF; Chapman KR
Ther Adv Respir Dis; 2019; 13():1753466619850725. PubMed ID: 31096854
[TBL] [Abstract][Full Text] [Related]
16. Aclidinium bromide and formoterol fumarate for the maintenance treatment of chronic obstructive pulmonary disease.
Haley R; Gupta N; Sethi S
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):103-113. PubMed ID: 31951778
[No Abstract] [Full Text] [Related]
17. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside.
Cazzola M; Calzetta L; Ora J; Puxeddu E; Rogliani P; Matera MG
Respir Med; 2015 Oct; 109(10):1305-11. PubMed ID: 26303336
[TBL] [Abstract][Full Text] [Related]
18. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of aclidinium/formoterol versus monotherapies and aclidinium versus placebo in Chinese and other Asian patients with moderate-to-severe COPD: The AVANT Phase 3 study.
Sun Y; Molins E; Daoud SZ; Trivedi R; Stewart C; Lamarca R; Bharali P; Garcia-Gil E
Respir Med; 2023 Nov; 218():107393. PubMed ID: 37640273
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
Medic G; Lindner L; van der Weijden M; Karabis A
Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
